Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial

口服免疫疗法 医学 花生过敏 安慰剂 免疫疗法 益生菌 口腔健康 口腔 不利影响 内科学 过敏 口服 临床试验 食物过敏 免疫学 安慰剂对照研究 随机对照试验 梅德林 临床研究阶段 花生酱
作者
Paxton Loke,Francesca Orsini,Adriana C Lozinsky,Michael Gold,Michael D O'Sullivan,Patrick Quinn,Melanie Lloyd,Sarah Ashley,Sigrid Pitkin,Christine Axelrad,Jessica R Metcalfe,Ee Lyn Su,Dean Tey,Marnie N Robinson,Katrina Jane Allen,Susan L. Prescott,Audrey DunnGalvin,Mimi L K Tang,Molly O'Sullivan,Susan Fahy-Scheer
出处
期刊:The Lancet Child & Adolescent Health [Elsevier BV]
卷期号:6 (3): 171-184 被引量:136
标识
DOI:10.1016/s2352-4642(22)00006-2
摘要

Summary

Background

Oral immunotherapy is effective at inducing desensitisation to allergens and induces sustained unresponsiveness (ie, clinical remission) in a subset of patients, but causes frequent reactions. We aimed to investigate whether addition of a probiotic adjuvant improved the efficacy or safety of peanut oral immunotherapy.

Methods

PPOIT-003, a multicentre, randomised, phase 2b trial, was conducted in three tertiary hospitals in Australia (Adelaide [SA], Melbourne [VIC], and Perth [WA]) in children aged 1–10 years, weighing more than 7 kg, with peanut allergy confirmed by a double-blind placebo-controlled food challenge (cumulative 4950 mg dose of peanut protein) and positive peanut skin prick test (≥3 mm) or peanut-specific IgE (≥0·35 kU/L). Children were randomly assigned (2:2:1) to receive probiotic and peanut oral immunotherapy (PPOIT), placebo probiotic and peanut oral immunotherapy (OIT), or placebo probiotic and placebo OIT (placebo) for 18 months, and were followed up until 12 months after completion of treatment. Oral immunotherapy consisted of increasing doses of peanut protein (commercially available food-grade 12% defatted peanut flour [50% peanut protein]) until a 2000 mg daily maintenance dose was reached. The probiotic adjuvant was a daily dose of 2 × 1010 colony-forming units of the probiotic Lactobacillus rhamnosus ATCC 53103. Placebo immunotherapy comprised maltodextrin, brown food colouring, and peanut essence, and placebo probiotic was maltodextrin. Dual primary outcomes were 8-week sustained unresponsiveness, defined as no reaction to a cumulative dose of 4950 mg peanut protein at treatment completion and 8 weeks after treatment completion, in the PPOIT versus placebo groups and the PPOIT versus OIT groups, analysed by intention to treat. Safety endpoints were adverse events during the treatment phase, and peanut ingestion and reactions in the 12-month post-treatment period. This study is registered with the Australian New Zealand Clinical Trials Registry, 12616000322437.

Findings

Between July 4, 2016, and Sept 21, 2020, 201 participants were enrolled and included in the intention-to-treat analysis. 36 (46%) of 79 children in the PPOIT group and 42 (51%) of 83 children in the OIT group achieved sustained unresponsiveness compared with two (5%) of 39 children in the placebo group (risk difference 40·44% [95% CI 27·46 to 53·42] for PPOIT vs placebo, p<0·0001), with no difference between PPOIT and OIT (−5·03% [–20·40 to 10·34], p=0·52). Treatment-related adverse events were reported in 72 (91%) of 79 children in the PPOIT group, 73 (88%) of 83 children in the OIT group, and 28 (72%) of 39 children in the placebo group. Exposure-adjusted incidence of adverse events was 10·58 in the PPOIT group, 11·36 in the OIT, and 2·09 in the placebo group (ratio 0·92 [95% CI 0·85 to 0·99] for PPOIT vs OIT, p=0·042; 4·98 [4·11–6·03] for PPOIT vs placebo, p<0·0001; 5·42 [4·48–6·56] for OIT vs placebo, p<0·0001), with differences seen primarily in gastrointestinal symptoms and in children aged 1–5 years. During the 12-month post-treatment period, 60 (85%) of 71 participants in the PPOIT group, 60 (86%) of 70 participants in the OIT group, and six (18%) of 34 participants in the placebo group were eating peanut; rescue epinephrine use was infrequent (two [3%] of 71 in the PPOIT group, four [6%] of 70 in the OIT group, and none in the placebo group).

Interpretation

Both PPOIT and OIT were effective at inducing sustained unresponsiveness. Addition of a probiotic did not improve efficacy of OIT, but might offer a safety benefit compared with OIT alone, particularly in preschool children.

Funding

National Health and Medical Research Council Australia and Prota Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
maT完成签到,获得积分10
1秒前
可爱千兰完成签到,获得积分10
1秒前
1秒前
龅牙苏完成签到,获得积分10
2秒前
2秒前
2秒前
corall完成签到,获得积分10
2秒前
2秒前
樊新竹完成签到,获得积分10
2秒前
ccczzz完成签到,获得积分10
3秒前
3秒前
荔枝烨发布了新的文献求助10
3秒前
沄霄之上发布了新的文献求助10
3秒前
今后的应助被小胖子采纳,获得10
3秒前
王海祥发布了新的文献求助10
4秒前
城南完成签到,获得积分10
4秒前
科目三的应助被Jenson采纳,获得10
5秒前
5秒前
5秒前
h11发布了新的文献求助10
5秒前
Akim的应助被小明同学采纳,获得10
5秒前
7秒前
乔木完成签到,获得积分10
7秒前
8秒前
小蘑菇的应助被白芷采纳,获得10
8秒前
8秒前
123456发布了新的文献求助10
8秒前
匿名完成签到,获得积分10
8秒前
8秒前
zcyuqing发布了新的文献求助10
9秒前
9秒前
9秒前
10秒前
10秒前
10秒前
10秒前
DW发布了新的文献求助10
11秒前
何hehe发布了新的文献求助10
11秒前
乔木发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9558007
关于积分的说明 21743214
捐赠科研通 7754605
什么是DOI,文献DOI怎么找? 3428426
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473048